Skip to main content

Table 4 Survival outcomes of patients with castration-resistant prostate cancer, stratified by clinical trial participation

From: Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: a multi-center analysis

  Overall
(n = 299)
Clinical trial
Participants
(n = 65)
Non-participants
(n = 234)
p
No. cancer-specific deaths 187 (62.5%) 44 (67.7%) 143 (61.1%) 0.364
2-year cancer-specific survival 46.8% 61.3% 42.4% 0.003
CRPC to death (months) 13.0 (6.0–24.3) 23.5 (13.3–30.5) 11.0 (5.0–19.3) < 0.001
Total follow-up (months) 16.0 (7.2–26.0) 26.0 (16.0–39.8) 13.5 (6.0–24.0) < 0.001
  1. Data are presented as number (%) or median (interquartile range)
  2. Abbreviations: CRPC castration-resistant prostate cancer